Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality

Sato,Hiromichi; Sato,Hiromichi; Meng,Sikun; Meng,Sikun; Sasaki,Kazuki; Sasaki,Kazuki; Kobayashi,Shogo; Kobayashi,Shogo; Kido,Kansuke; Kido,Kansuke; Tsuji,Yoshiko; Tsuji,Yoshiko; Arao,Yasuko; Arao,Yasuko; Saito,Yoshiko; Saito,Yoshiko; Iwagami,Yoshifumi; Iwagami,Yoshifumi; Yamada,Daisaku; Yamada,Daisaku; Tomimaru,Yoshito; Tomimaru,Yoshito; Noda,Takehiro; Noda,Takehiro; Takahashi,Hidenori; Takahashi,Hidenori; Motooka,Daisuke; Motooka,Daisuke; Uchida,Shizuka; Uchida,Shizuka; Ofusa,Ken; Ofusa,Ken; Satoh,Taroh; Satoh,Taroh; Doki,Yuichiro; Doki,Yuichiro; Eguchi,Hidetoshi; Eguchi,Hidetoshi; Hara,Tomoaki; Hara,Tomoaki; Ishii,Hideshi; Ishii,Hideshi

doi:10.3892/ijo.2024.5662

Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality

Authors:
- Hiromichi Sato
- Sikun Meng
- Kazuki Sasaki
- Shogo Kobayashi
- Kansuke Kido
- Yoshiko Tsuji
- Yasuko Arao
- Yoshiko Saito
- Yoshifumi Iwagami
- Daisaku Yamada
- Yoshito Tomimaru
- Takehiro Noda
- Hidenori Takahashi
- Daisuke Motooka
- Shizuka Uchida
- Ken Ofusa
- Taroh Satoh
- Yuichiro Doki
- Hidetoshi Eguchi
- Tomoaki Hara
- Hideshi Ishii
View Affiliations

Affiliations: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, Department of Pathology, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka 565‑0871, Japan, Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, DK‑2450 Copenhagen, Denmark
Published online on: June 6, 2024 https://doi.org/10.3892/ijo.2024.5662
Article Number: 74
Copyright: © Sato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Signal recognition particles (SRPs) are essential for regulating intracellular protein transport and secretion. Patients with tumors with high SRP9 expression tend to have a poorer overall survival. However, to the best of our knowledge, no reports have described the relationship between SRP9 localization and prognosis in pancreatic cancer. Thus, the present study aimed to investigate this relationship. Immunohistochemical staining for SRP9 using excised specimens from pancreatic cancer surgery cases without preoperative chemotherapy or radiotherapy showed that SRP9 was preferentially expressed in the nucleus of the cancerous regions in some cases, which was hardly detected in other cases, indicating that SRP9 was transported to the nucleus in the former cases. To compare the prognosis of patients with SRP9 nuclear translocation, patients were divided into two groups: Those with a nuclear translocation rate of >50% and those with a nuclear translocation rate of ≤50%. The nuclear translocation rate of >50% group had a significantly better recurrence‑free survival than the nuclear translocation rate of ≤50% group (P=0.037). Subsequent in vitro experiments were conducted; notably, the nuclear translocation rate of SRP9 was reduced under amino acid‑deficient conditions, suggesting that multiple factors are involved in this phenomenon. To further study the function of SRP9 nuclear translocation, in vitro experiments were performed by introducing SRP9 splicing variants (v1 and v2) and their deletion mutants lacking C‑terminal regions into MiaPaCa pancreatic cancer cells. The results demonstrated that both splicing variants showed nuclear translocation regardless of the C‑terminal deletions, suggesting the role of the N‑terminal regions. Given that SRP9 is an RNA‑binding protein, the study of RNA immunoprecipitation revealed that signaling pathways involved in cancer progression and protein translation were downregulated in nuclear‑translocated v1 and v2. Undoubtedly, further studies of the nuclear translocation of SRP9 will open an avenue to optimize the precise evaluation and therapeutic control of pancreatic cancer.

View Figures

View References

1	Kellogg MK, Tikhonova EB and Karamyshev AL: Signal recognition particle in human diseases. Front Genet. 13:8980832022. View Article : Google Scholar : PubMed/NCBI
2	Erdogan G, Trabulus DC, Talu CK and Guven M: Investigation of SRP9 protein expression in breast cancer. Mol Biol Rep. 49:531–537. 2022. View Article : Google Scholar
3	Rho JH, Qin S, Wang JY and Roehrl MH: Proteomic expression analysis of surgical human colorectal cancer tissues: Up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res. 7:2959–2972. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zhang M, Peng Y, Yang Z, Zhang H, Xu C, Liu L, Zhao Q, Wu J, Wang H and Liu J: DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. BMC Cancer. 22:5612022. View Article : Google Scholar : PubMed/NCBI
5	Hessel EV, de Wit M, Wolterink-Donselaar IG, Karst H, de Graaff E, van Lith HA, de Bruijn E, de Sonnaville S, Verbeek NE, Lindhout D, et al: Identification of Srp9 as a febrile seizure susceptibility gene. Ann Clin Transl Neurol. 1:239–250. 2014. View Article : Google Scholar
6	Bovia F, Fornallaz M, Leffers H and Strub K: The SRP9/14 subunit of the signal recognition particle (SRP) is present in more than 20-fold excess over SRP in primate cells and exists primarily free but also in complex with small cytoplasmic Alu RNAs. Mol Biol Cell. 6:471–484. 1995. View Article : Google Scholar : PubMed/NCBI
7	Berger A, Ivanova E, Gareau C, Scherrer A, Mazroui R and Strub K: Direct binding of the Alu binding protein dimer SRP9/14 to 40S ribosomal subunits promotes stress granule formation and is regulated by Alu RNA. Nucleic Acids Res. 42:11203–11217. 2014. View Article : Google Scholar : PubMed/NCBI
8	Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, Benci JL, DeMichele AM, Tchou J, Marcotrigiano J and Minn AJ: Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell. 170:352–366 e13. 2017. View Article : Google Scholar : PubMed/NCBI
9	Sugimura T, Birnbaum SM, Winitz M and Greenstein JP: Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys. 81:448–455. 1959. View Article : Google Scholar : PubMed/NCBI
10	Kaiser P: Methionine dependence of cancer. Biomolecules. 10:5682020. View Article : Google Scholar : PubMed/NCBI
11	Wang Z, Yip LY, Lee JHJ, Wu Z, Chew HY, Chong PKW, Teo CC, Ang HY, Peh KLE, Yuan J, et al: Methionine is a metabolic dependency of tumor-initiating cells. Nat Med. 25:825–837. 2019. View Article : Google Scholar : PubMed/NCBI
12	Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JP Jr, Ciccarella A, Calcagnotto A, Mikhael PG, et al: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572:397–401. 2019. View Article : Google Scholar : PubMed/NCBI
13	Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, Nwosu ZC, Zhang L, Czerwonka A, Pawłowska A, et al: Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 585:277–282. 2020. View Article : Google Scholar : PubMed/NCBI
14	Tatekawa S, Ofusa K, Chijimatsu R, Vecchione A, Tamari K, Ogawa K and Ishii H: Methylosystem for cancer sieging strategy. Cancers (Basel). 13:50882021. View Article : Google Scholar : PubMed/NCBI
15	Kilgour MK, MacPherson S, Zacharias LG, Ellis AE, Sheldon RD, Liu EY, Keyes S, Pauly B, Carleton G, Allard B, et al: 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. Sci Adv. 7:eabe11742021. View Article : Google Scholar : PubMed/NCBI
16	Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, et al: Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations. Blood. 132:1225–1240. 2018. View Article : Google Scholar : PubMed/NCBI
17	Figg JW, Barajas JM and Obeng EA: Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol. 28:73–79. 2021. View Article : Google Scholar : PubMed/NCBI
18	Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M, Hogg SJ, Bewersdorf JP, Han C, Singer ME, et al: Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 41:164–180 e8. 2023. View Article : Google Scholar :
19	Rahman MA, Lin KT, Bradley RK, Abdel-Wahab O and Krainer AR: Recurrent SRSF2 mutations in MDS affect both splicing and NMD. Genes Dev. 34:413–427. 2020. View Article : Google Scholar : PubMed/NCBI
20	Yang Q, Zhao J, Zhang W, Chen D and Wang Y: Aberrant alternative splicing in breast cancer. J Mol Cell Biol. 11:920–929. 2019. View Article : Google Scholar : PubMed/NCBI
21	Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, et al: Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 132:e1450992022. View Article : Google Scholar : PubMed/NCBI
22	Wan L, Lin KT, Rahman MA, Ishigami Y, Wang Z, Jensen MA, Wilkinson JE, Park Y, Tuveson DA and Krainer AR: Splicing Factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discov. 13:1678–1695. 2023. View Article : Google Scholar : PubMed/NCBI
23	Tan C, Cao J, Chen L, Xi X, Wang S, Zhu Y, Yang L, Ma L, Wang D, Yin J, et al: Noncoding RNAs serve as diagnosis and prognosis biomarkers for hepatocellular carcinoma. Clin Chem. 65:905–915. 2019. View Article : Google Scholar : PubMed/NCBI
24	Johnson LR, Lee DY, Eacret JS, Ye D, June CH and Minn AJ: The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. 184:4981–4995 e14. 2021. View Article : Google Scholar : PubMed/NCBI
25	Xie X, Liu H, Wang Y, Zhou Y, Yu H, Li G, Ruan Z, Li F, Wang X and Zhang J: Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. Oncotarget. 7:45837–45848. 2016. View Article : Google Scholar : PubMed/NCBI
26	Novak Kujundzic R, Prpic M, Dakovic N, Dabelić N, Tomljanović M, Mojzeš A, Fröbe A and Trošelj KG: Nicotinamide N-Methyltransferase in acquisition of stem cell properties and therapy resistance in cancer. Int J Mol Sci. 22:56812021. View Article : Google Scholar : PubMed/NCBI
27	Rodrigues F, van Hemert M, Steensma HY, Corte-Real M and Leao C: Red fluorescent protein (DsRed) as a reporter in Saccharomyces cerevisiae. J Bacteriol. 183:3791–3794. 2001. View Article : Google Scholar : PubMed/NCBI
28	Kimura A, Toda Y, Matsumoto Y, Yamamoto H, Yahiro K, Shimada E, Kanahori M, Oyama R, Fukushima S, Nakagawa M, et al: Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone. Sci Rep. 12:134382022. View Article : Google Scholar
29	Larsson SC, Giovannucci E and Wolk A: Methionine and vitamin B6 intake and risk of pancreatic cancer: A prospective study of Swedish women and men. Gastroenterology. 132:113–118. 2007. View Article : Google Scholar : PubMed/NCBI
30	Wei DH and Mao QQ: Vitamin B6, vitamin B12 and methionine and risk of pancreatic cancer: A meta-analysis. Nutr J. 19:1112020. View Article : Google Scholar : PubMed/NCBI
31	Kellogg MK, Miller SC, Tikhonova EB and Karamyshev AL: SRPassing Co-translational Targeting: The role of the signal recognition particle in protein targeting and mRNA protection. Int J Mol Sci. 22:62842021. View Article : Google Scholar : PubMed/NCBI
32	Ala M: Target c-Myc to treat pancreatic cancer. Cancer Biol Ther. 23:34–50. 2022. View Article : Google Scholar : PubMed/NCBI
33	Peng YP, Zhu Y, Yin LD, Zhang JJ, Wei JS, Liu X, Liu XC, Gao WT, Jiang KR and Miao Y: PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. J Exp Clin Cancer Res. 36:302017. View Article : Google Scholar : PubMed/NCBI
34	Oshi M, Patel A, Le L, Tokumaru Y, Yan L, Matsuyama R, Endo I and Takabe K: G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Am J Cancer Res. 11:3070–3084. 2021.PubMed/NCBI
35	Ashton TM, McKenna WG, Kunz-Schughart LA and Higgins GS: Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 24:2482–2490. 2018. View Article : Google Scholar : PubMed/NCBI
36	Long D, Chen K, Yang Y and Tian X: Unfolded protein response activated by endoplasmic reticulum stress in pancreatic cancer: Potential therapeutical target. Front Biosci (Landmark Ed). 26:1689–1696. 2021. View Article : Google Scholar
37	Luo J: KRAS mutation in pancreatic cancer. Semin Oncol. 48:10–18. 2021. View Article : Google Scholar : PubMed/NCBI
38	Brierley J, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. Wiley Blackwell; Hoboken, NJ: 2017